Dr Margaret Centenera

Research Fellow

South Australian Immunogenomics Cancer Institute

Faculty of Health and Medical Sciences

Eligible to supervise Masters and PhD - email supervisor to discuss availability.

My Research
Career
Publications
Grants and Funding
Teaching
Supervision
Professional Activities
Contact

Dr Centenera is a Research Fellow in the Prostate Cancer Research Group located at the South Australian Health and Medical Research Institute. Her research is focused on improving treatments for men with prostate cancer. This involves understanding and targeting the androgen receptor in prostate cancer cells, and identifying more accurate markers for monitoring patient response to current and emerging prostate cancer therapeutics. Dr Centenera is an expert in patient-derived explants as a preclinical model of prostate cancer.

Appointments

Date	Position	Institution name
2016 - ongoing	Research Fellow	University of Adelaide
2013 - 2015	Prostate Cancer Foundation of Australia Young Investigator	University of Adelaide
2008 - 2012	Postdoctoral Research Officer	University of Adelaide
2007 - 2008	Research Associate	University of Adelaide

Awards and Achievements

Date	Type	Title	Institution Name	Country	Amount
2016	Invitation	Markers in Cancer Diagnostic Development Tutorial	American Society of Clinical Oncology	United States	-
2015	Award	School of Medicine Travel Grant	University of Adelaide	Australia	-
2013	Award	Beat Cancer Project Travel Award	South Australia Heart and Medical Research Institute	Australia	-
2012	Fellowship	School of Medicine Travel Grants	University of Adelaide	Australia	-
2010	Award	Travel Grant	Prostate Cancer Foundation of Australia	Australia	-
2008	Recognition	Letter of Commendation-PhD Thesis Examiner	University of Adelaide	Australia	-
2006	Award	School of Molecular and Biomedical Science Postgraduate Conference Travel Award	University of Adelaide	Australia	-
2004	Award	Travel Award	The Lorne Cancer Conference	-	-
2004	Scholarship	Faculty of Health Sciences PhD Scholarship	University of Adelaide	Australia	-
2003	Scholarship	Honours Research Scholarhip	The Queen Elizabeth Hospital	Australia	-
2003	Recognition	Best Honours Presentation	The Queen Elizabeth Hospital	Australia	-

Education

Date	Institution name	Country	Title
2004 - 2008	Department of Physiology	Australia	Doctor of Philosophy
2003 - 2003	Department of Physiology	Australia	Bachelor of Science with First Class Honours
1997 - 2001	University of Adelaide	Australia	Bachelor of Health Science

Research Interests

Cancer Biology and Clinical Oncology Men's Health Translational Health Outcomes Biomarkers Cancer Cell Biology Cancer Therapy

Journals

Year	Citation
2024	Lin, H. -M., Yang, X., Centenera, M. M., Huynh, K., Giles, C., Dehairs, J., . . . Horvath, L. G. (2024). Circulating Lipid Profiles Associated With Resistance to Androgen Deprivation Therapy in Localized Prostate Cancer. JCO Precision Oncology, 8(8), e2400260-1-e2400260-11. DOI Scopus2 Europe PMC2
2024	Rahman, R., Rahaman, M. H., Hanson, A. R., Choo, N., Xie, J., Townley, S. L., . . . Selth, L. A. (2024). CDK9 inhibition inhibits multiple oncogenic transcriptional and epigenetic pathways in prostate cancer. British Journal of Cancer, 131(6), 1092-1105. DOI Scopus1
2024	Rahman, R., Rahaman, M. H., Hanson, A. R., Choo, N., Xie, J., Townley, S. L., . . . Selth, L. A. (2024). Author Correction: CDK9 inhibition constrains multiple oncogenic transcriptional and epigenetic pathways in prostate cancer.. Br J Cancer, 131(10), 1719. DOI
2023	Shin, S. Y., Centenera, M. M., Hodgson, J. T., Nguyen, E. V., Butler, L. M., Daly, R. J., & Nguyen, L. K. (2023). A Boolean-based machine learning framework identifies predictive biomarkers of HSP90-targeted therapy response in prostate cancer. Frontiers in Molecular Biosciences, 10, 1094321-1-1094321-16. DOI Scopus5 WoS1 Europe PMC2
2023	Hinneh, J. A., Gillis, J. L., Mah, C. Y., Irani, S., Shrestha, R. K., Ryan, N. K., . . . Butler, L. M. (2023). Targeting hyaluronan-mediated motility receptor (HMMR) enhances response to androgen receptor signalling inhibitors in prostate cancer. British Journal of Cancer, 129(8), 1350-1361. DOI Scopus4 Europe PMC2
2022	Centenera, M. M., Vincent, A. D., Moldovan, M., Lin, H. M., Lynn, D. J., Horvath, L. G., & Butler, L. M. (2022). Harnessing the Heterogeneity of Prostate Cancer for Target Discovery Using Patient-Derived Explants. Cancers, 14(7), 1-18. DOI Scopus10 WoS2 Europe PMC10
2022	Hinneh, J. A., Gillis, J. L., Moore, N. L., Butler, L. M., & Centenera, M. M. (2022). The role of RHAMM in cancer: Exposing novel therapeutic vulnerabilities. Frontiers in Oncology, 12, 1-14. DOI Scopus15 WoS3 Europe PMC10
2021	Kwan, K. H., Burvenich, I. J. G., Centenera, M. M., Goh, Y. W., Rigopoulos, A., Dehairs, J., . . . Ackermann, U. (2021). Synthesis and fluorine-18 radiolabeling of a phospholipid as a PET imaging agent for prostate cancer. Nuclear medicine and biology, 93, 37-45. DOI Scopus3 WoS3 Europe PMC1
2021	Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S., . . . Swinnen, J. V. (2021). Lipidomic profiling of clinical prostate cancer reveals targetable alterations in membrane lipid composition. Cancer Research, 81(19), 4981-4993. DOI Scopus50 WoS26 Europe PMC37
2021	Centenera, M. M., Scott, J. S., Machiels, J., Nassar, Z. D., Miller, D. C., Zinonos, I., . . . Butler, L. M. (2021). ELOVL5 is a critical and targetable fatty acid elongase in prostate cancer. Cancer Research, 81(7), 1704-1718. DOI Scopus54 WoS36 Europe PMC37
2021	Lin, H. -M., Huynh, K., Kohli, M., Tan, W., Azad, A. A., Yeung, N., . . . Horvath, L. G. (2021). Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer. Prostate Cancer and Prostatic Diseases, 24(3), 860-870. DOI Scopus20 WoS12 Europe PMC14
2021	Gillis, J. L., Hinneh, J. A., Ryan, N. K., Irani, S., Moldovan, M., Quek, L. -E., . . . Butler, L. M. (2021). A feedback loop between the androgen receptor and 6-phosphogluoconate dehydrogenase (6PGD) drives prostate cancer growth. eLife, 10, e62592-1-e62592-27. DOI Scopus22 WoS12 Europe PMC18
2020	Scheinberg, T., Kench, J., Stockler, M., Mahon, K. L., Sebastian, L., Stricker, P., . . . Horvath, L. G. (2020). Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer). BMJ Open, 10(1), e033667-1-e033667-6. DOI Scopus13 WoS12 Europe PMC10
2020	Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (2020). Fatty acid oxidation is an adaptive survival pathway induced in prostate tumors by heat shock protein 90 inhibition. Molecular cancer research : MCR, 18(10), 1500-1511. DOI Scopus16 WoS10 Europe PMC10
2020	Nassar, Z. D., Mah, C. Y., Dehairs, J., Burvenich, I. J., Irani, S., Centenera, M. M., . . . Butler, L. M. (2020). Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis. Elife, 9, 1-34. DOI Scopus122 WoS70 Europe PMC81
2019	Nassar, Z. D., Mah, C. Y., Dehairs, J., Burvenich, I. J. G., Irani, S., Centenera, M. M., . . . Butler, L. M. (2019). DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis. DOI
2019	Balaban, S., Nassar, Z. D., Zhang, A. Y., Hosseini-Beheshti, E., Centenera, M. M., Schreuder, M., . . . Hoy, A. J. (2019). Extracellular fatty acids are the major contributor to lipid synthesis in prostate cancer. Molecular Cancer Research, 17(4), 949-962. DOI Scopus63 WoS53 Europe PMC46
2019	Mutuku, S. M., Trim, P. J., Prabhala, B. K., Irani, S., Bremert, K. L., Logan, J. M., . . . Butler, L. M. (2019). Evaluation of small molecule drug uptake in patient-derived prostate cancer explants by mass spectrometry. Scientific Reports, 9(1), 15008. DOI Scopus13 WoS9 Europe PMC9
2018	Lin, H., Lee, B., Castillo, L., Spielman, C., Grogan, J., Yeung, N., . . . Daly, R. (2018). Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer. The Prostate, 78(4), 308-317. DOI Scopus52 WoS43 Europe PMC32
2018	Armstrong, H., Gillis, J., Johnson, I., Nassar, Z., Moldovan, M., Levrier, C., . . . Butler, L. (2018). Dysregulated fibronectin trafficking by Hsp90 inhibition restricts prostate cancer cell invasion. Scientific reports, 8(1), 2090-1-2090-14. DOI Scopus31 WoS26 Europe PMC23
2018	Centenera, M., Selth, L., Ebrahimie, E., Butler, L., & Tilley, W. (2018). New opportunities for targeting the androgen receptor in prostate cancer. Cold Spring Harbor Perspectives in Medicine, 10(12), 1-19. DOI Scopus22 WoS18 Europe PMC15
2018	Nguyen, E., Centenera, M., Moldovan, M., Das, R., Irani, S., Vincent, A., . . . Butler, L. (2018). Identification of novel response and predictive biomarkers to Hsp90 inhibitors through mass spectrometry-based proteomic profiling of patient-derived prostate tumor explants. Molecular & cellular proteomics : MCP, 17(8), 1470-1486. DOI Scopus27 WoS25 Europe PMC19
2018	Shafi, A., Schiewer, M., de Leeuw, R., Dlygeri, E., McCue, P., Shah, N., . . . Knudsen, K. (2018). Novel patient derived models reveal the impact of the tumor microenvironment on therapeutic response. European Urology Oncology, 1(4), 325-337. DOI Scopus38 WoS34 Europe PMC35
2018	Centenera, M. M., Hickey, T. E., Jindal, S., Ryan, N. K., Ravindranathan, P., Mohammed, H., . . . Tilley, W. D. (2018). A patient-derived explant (PDE) model of hormone-dependent cancer. Molecular Oncology, 12(9), 1608-1622. DOI Scopus91 WoS65 Europe PMC70
2017	Selth, L., Das, R., Townley, S., Coutinho, I., Hanson, A., Centenera, M., . . . Tilley, W. (2017). A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer. Oncogene, 36(1), 24-34. DOI Scopus91 WoS84 Europe PMC61
2017	Tran, L. N., Kichenadasse, G., Butler, L. M., Centenera, M. M., Morel, K. L., Ormsby, R. J., . . . Sykes, P. J. (2017). The combination of metformin and valproic acid induces synergistic apoptosis in the presence of p53 and androgen signaling in prostate cancer. Molecular cancer therapeutics, 16(12), 2689-2700. DOI Scopus26 WoS22 Europe PMC14
2016	Armstrong, H., Koay, Y., Irani, S., Das, R., Nassar, Z., The Australian Prostate Cancer BioResource., . . . Butler, L. (2016). A novel class of Hsp90 C-terminal modulators have pre-clinical efficacy in prostate tumor cells without induction of a heat shock response. Prostate, 76(16), 1546-1559. DOI Scopus21 WoS21 Europe PMC16
2016	Carter, S., Centenera, M., Tilley, W., Selth, L., & Butler, L. (2016). IκBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor. BMC Cancer, 16(1), 141-1-141-13. DOI Scopus12 WoS11 Europe PMC7
2016	Carter, S. L., Centenera, M. M., Tilley, W. D., Selth, L. A., & Butler, L. M. (2016). Erratum to: IΚBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor.[BMC Cancer. 2016] 16:141. Doi: 10.1186/s12885-016-2188-2.. BMC Cancer, 16(1), 1 page. DOI Europe PMC1
2016	Butler, L., Centenera, M., & Swinnen, J. (2016). Androgen control of lipid metabolism in prostate cancer: novel insights and future applications. Endocrine-Related Cancer, 23(5), 219-227. DOI Scopus98 WoS75 Europe PMC70
2015	Centenera, M., Carter, S., Gillis, J., Marrocco-Tallarigo, D., Grose, R., Tilley, W., & Butler, L. (2015). Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms. Endocrine-Related Cancer, 22(5), 805-818. DOI Scopus24 WoS23 Europe PMC18
2015	Butler, L., Ferraldeschi, R., Armstrong, H., Centenera, M., & Workman, P. (2015). Maximizing the therapeutic potential of HSP90 inhibitors. Molecular Cancer Research, 13(11), 1445-1451. DOI Scopus161 WoS140 Europe PMC123
2013	Centenera, M., Fitzpatrick, A., Tilley, W., & Butler, L. (2013). Hsp90: still a viable target in prostate cancer. Biochimica et Biophysica Acta-Reviews on Cancer, 1835(2), 211-218. DOI Scopus45 WoS39 Europe PMC28
2013	Comstock, C., Augello, M., Goodwin, J., de Leeuw, R., Schiewer, M., Ostrander, W., . . . Knudsen, K. (2013). Targeting cell cycle and hormone receptor pathways in cancer. Oncogene, 32(48), 5481-5491. DOI Scopus95 WoS79 Europe PMC72
2013	Centenera, M., Raj, G., Knudsen, K., Tilley, W., & Butler, L. (2013). Ex vivo culture of human prostate tissue and drug development. Nature Reviews, Urology, 10(8), 483-487. DOI Scopus113 WoS103 Europe PMC97
2013	Gillis, J., Selth, L., Centenera, M., Townley, S., Sun, S., Plymate, S., . . . Butler, L. (2013). Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors. Oncotarget, 4(5), 691-704. DOI Scopus49 WoS45 Europe PMC39
2013	Ravindranathan, P., Lee, T., Yang, L., Centenera, M., Butler, L., Tilley, W., . . . Raj, G. (2013). Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer. Nature Communications, 4(5), 1923-1-1923-11. DOI Scopus118 WoS111 Europe PMC83
2012	Schiewer, M., Goodwin, J., Han, S., Brenner, J., Augello, M., Dean, J., . . . Knudsen, K. (2012). Dual roles of PARP-1 promote cancer growth and progression. Cancer Discovery, 2(12), 1134-1149. DOI Scopus341 WoS299 Europe PMC252
2012	Centenera, M., Gillis, J., Hanson, A., Jindal, S., Taylor, R., Risbridger, G., . . . Butler, L. (2012). Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Clinical Cancer Research, 18(13), 3562-3570. DOI Scopus94 WoS89 Europe PMC74
2011	Chiam, K., Centenera, M., Butler, L., Tilley, W., & Bianco-Miotto, T. (2011). GSTP1 DNA methylation and expression status is indicative of 5-aza-2'-deoxycytidine efficacy in human prostate cancer cells. PLoS One, 6(9), e25634-1-e25634-11. DOI Scopus46 WoS36 Europe PMC31
2009	Marrocco, D., Centenera, M., Scher, H., Tilley, W., & Butler, L. (2009). Finding the place of histone deacetylase inhibitors in prostate cancer therapy. Expert Review of Clinical Pharmacology, 2(6), 619-630. DOI Scopus5 Europe PMC4
2009	Peters, A., Buchanan, G., Ricciardelli, C., Bianco-Miotto, T., Centenera, M., Harris, J., . . . Tilley, W. (2009). Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Research, 69(15), 6131-6140. DOI Scopus336 WoS295 Europe PMC225
2008	Centenera, M., Harris, J., Tilley, W., & Butler, L. (2008). The Contribution of Different Androgen Receptor Domains to Receptor Dimerization and Signaling. Molecular Endocrinology, 22(11), 2373-2382. DOI Scopus119 WoS103 Europe PMC79
2006	Butler, L., Centenera, M., Neufing, P., Buchanan, G., Choong, C., Ricciardelli, C., . . . Tilley, W. (2006). Suppression of androgen receptor signaling in prostate cancer cells by an inhibitory receptor variant. Molecular Endocrinology, 20(5), 1009-1024. DOI Scopus15 WoS14 Europe PMC11

Book Chapters

Year	Citation
2014	Moore, N., Centenera, M., Butler, L., Hickey, T., & Tilley, W. (2014). Androgens and the androgen receptor (AR). In E. Gelmann, C. Sawyers, & F. Rauscher (Eds.), Molecular oncology: Causes of cancer and targets for treatment (1 ed., pp. 378-391). Cambridge, United Kingdom: Cambridge University Press. DOI
2009	Buchanan, G., Need, E., Bianco-Miotto, T., Greenberg, N., Scher, H., Centenera, M., . . . Tilley, W. (2009). Insights from AR gene mutations. In D. Tindall, & J. Mohler (Eds.), Androgen action in prostate cancer (pp. 207-240). Dordrecht, Netherlands: Springer. DOI Scopus4

Conference Papers

Year	Citation
2017	Nassar, Z. D., Centenera, M. M., Machiels, J., Polacek, S. J., Bloch, K., Tilley, W. D., . . . Butler, L. (2017). Lipid elongation: an unexplored therapeutic target in prostate cancer. In CANCER RESEARCH Vol. 77 (pp. 2 pages). Washington, DC: AMER ASSOC CANCER RESEARCH. DOI
2017	Tran, L. N. K., Kichenadasse, G., Ormsby, R. J., Morel, K. L., Butler, L. M., Centenera, M. M., & Sykes, P. J. (2017). COMBINATION OF METFORMIN AND SODIUM VALPROATE FOR PROSTATE CANCER: A RAPID APPROACH FROM BENCH TO CLINICAL TRIAL.. In JOURNAL OF UROLOGY Vol. 197 (pp. E1108-E1109). Boston, MA: ELSEVIER SCIENCE INC. DOI
2009	Butler, L., Centenera, M., Marrocco, D., Carter, S., Bianco-Miotto, T., & Tilley, W. (2009). A novel combinatorial approach using androgen receptor-targeted agents for treatment of prostate cancer. In Cancer Research Vol. 69 (pp. 2 pages). American Association for Cancer Research.

Conference Items

Year	Citation
2022	Strach, M. C., Yeung, N., Lin, H. -M., Ansari, N., Koh, C., Shin, J. -S., . . . Mahon, K. (2022). Patient-derived explant model of appendiceal cancer.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS.
2020	Lin, H. -M., Huynh, K., Kohli, M., Tan, W., Azad, A., Yeung, N., . . . Horvath, L. (2020). Lipidomic analysis of circulating lipids across the natural history of prostate cancer identifies aberrant ceramide metabolism. Poster session presented at the meeting of Abstracts of the Mini Annual Scientific Meeting ANZUP 2020, as published in Asia-Pacific Journal of Clinical Oncology. Adelaide, SA: Wiley.
2020	Butler, L. M., Mah, C. Y., Dehairs, J., Vincent, A., Mutuku, S., Spotbeen, X., . . . Swinnen, J. (2020). Phospholipid profiling of clinical prostate tissues reveals targetable alterations in membrane lipid composition accompanying tumorigenesis. Poster session presented at the meeting of CANCER RESEARCH. ELECTR NETWORK: AMER ASSOC CANCER RESEARCH. DOI
2020	Mah, C. Y., Nassar, Z. D., Burvenich, I. J., Irani, S., Centenera, M. M., Moldovan, M., . . . Butler, L. M. (2020). DECR1: The rate limiting enzyme of polyunsaturated fatty acid metabolism and a novel therapeutic target in prostate cancer. Poster session presented at the meeting of CANCER RESEARCH. ELECTR NETWORK: AMER ASSOC CANCER RESEARCH. DOI
2019	Scheinberg, T., Kench, J., Stockler, M., Mahon, K. L., Sebastian, L., Stricker, P., . . . Horvath, L. G. (2019). Pharmacodynamics Effects of CDK4/6 Inhibitor LEE011 (Ribociclib) in High-Risk, Localised Prostate Cancer: A Study Protocol for a Randomised Controlled Phase II Trial (Leep Study). Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
2019	Butler, L., Irani, S., Centenera, M., Ryan, N., Pegg, N., & Brooks, A. N. (2019). Preclinical investigation of a small molecule inhibitor of p300/CBP reveals efficacy in patient-derived prostate tumor explants.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS2
2018	Mutuku, S. M., Centenera, M. M., Trim, P. J., Snel, M. F., & Butler, L. M. (2018). Evaluation of small molecule drug uptake in <i>ex vivo</i> cultured clinical prostate tumours by mass spectrometry. Poster session presented at the meeting of BJU INTERNATIONAL. Brisbane, AUSTRALIA: WILEY.
2018	Nassar, Z. D., Centenera, M. M., Machiels, J., Zinonos, I., Hanson, A., Bloch, K., . . . Swinnen, J. V. (2018). Lipid elongation in prostate cancer is androgen regulated and a potential therapeutic target. Poster session presented at the meeting of BJU International. Brisbane, Australia: Wiley.
2017	Mutuku, S. M., Prabhala Bala., Centenera, M., Trim, P., Snel, M., & Butler, L. (2017). Quantification of Enzalutamide in Cultured Prostate Tissue Using LC-MS/MS. Poster session presented at the meeting of 26th Australian and New Zealand Society for Mass Spectrometry. Flinders University.
2017	Mutuku, S. M., Centenera, M., Trim, P., Gustafsson, O. J., Snel, M., & Butler, L. (2017). A Mass Spectrometry Approach to Characterise Lipid Composition in Prostate Tumuors. Poster session presented at the meeting of 11th Florey Postgraduate Research Conference. Adelaide.
2016	Nassar, Z. D., Centenera, M. M., Machiels, J., Polacek, S. J., Bloch, K., Tilley, W. D., . . . Swinnen, J. V. (2016). Androgenic regulation of lipid elongation in prostate cancer. Poster session presented at the meeting of BJU International. Melbourne: Wiley.
2015	Armstrong, H., Butler, L., Selth, L., Tarulli, G., & Centenera, M. (2015). The Hsp90 inhibitor, NVP-AUY922, produces anti-tumour activity through inhibition of fibronectin polymerization resulting in cytoskeletal reorganization. Poster session presented at the meeting of BJU INTERNATIONAL. Cairns, AUSTRALIA: WILEY-BLACKWELL.
2010	Centenera, M. M., Treloar, J. L., Hanson, A., Sutherland, P., Tilley, W. D., & Butler, L. M. (2010). Evaluation of the synthetic heat shock protein 90 inhibitors NVP-AUY922 and NVP-HSP990 in human prostate cancer tissue. Poster session presented at the meeting of European Journal of Cancer Supplements. Berlin, Germany: Elsevier. DOI

Date	Project	Investigators	Funding body	Amount
2023-2025	Targeting the metabolic adaptations that drive anti-androgen resistance in prostate cancer	Holst J, Centenera MM	Cancer Council NSW	$668,309
2023-2024	Unravelling the cellular and spatial heterogeneity in prostate cancer to unravel drivers of disease progression and treatment resistance.	Mah CY, Centenera MM, Butler LM, Lynn DJ	The Hospital Research Foundation	$125,000
2022-2024	A patient-derived discovery platform for companion biomarker development in prostate cancer.	Butler LM, Centenera MM, Horvath LG	Cancer Council NSW	$433,228
2021-2022	A patient-derived discovery platform for companion biomarker development in prostate cancer.	Centenera MM, Butler LM, Horvath LG	The Hospital Research Foundation	$149,662
2019-2021	PRECEPT - PRostatE CancEr Prognosis and Treatment	Corcorran N, Boutros P, Bristow R, Centenera MM, Collins I, Eeles R, Hayes V, Hovens C, Ijzerman M, Papenfuss T, Parker B, Park D, Pope B, Sweeney C, Tran B	Movember Foundation - Prostate Cancer Research Alliance	$5,250,000
2019	Generation of a protein signature of sensitivity in prostate cancer	Centenera MM	University of Adelaide	$39,800
2018 - 2020	Novel co-extinction strategies for treatment of prostate cancer	Butler LM, Lynn DJ, Hayes VM, Horvath LG, Mills IG, Centenera MM	Cancer Australia	$596,409
2015 - 2017	Exploiting alterations in lipid metabolism to improve diagnosis, treatment and molecular imaging of prostate cancer	Butler LM, Swinnen JV, Tilley WD, Scott AM, Hoy AJ and Wittert GA Co-Leads: Centenera MM, Selth LA, Dhomen N, Soekmadji C	Movember Foundation / Prostate Cancer Foundation of Australia (MRTA3	$3,250,000
2015 - 2017	Molecular hallmarks of heat shock protein 90 inhibition in prostate cancer	Butler LM, Daly R, Tilley WD, Horvath LG, Centenera MM	Cancer Australia (APP1085471)	$553,483
2013 - 2015	Explant technology for biomarker discovery of androgen receptor targeted therapies	Centenera MM	Prostate Cancer Foundation of Australia Young Investigator Grant (YIG0412)	$450,000
2013	Evaluation of biomarkers of response to Hsp90 inhibition in human prostate cancer	Centenera MM and Butler LM	Royal Adelaide Hospital Clinical Project Grant	$40,000
2012 - 2014	Exploiting metabolic alterations to more accurately monitor prostate cancer therapy	Butler LM, Centenera MM, Claessens F, Swinnen J	Prostate Cancer Foundation of Australia New Directions Development Award (NDDA 2711)	$299,817
2011	Identification of biomarkers of response to Hsp90 inhibition in human prostate cancer.	Centenera MM, Butler LM and Tilley WD.	Royal Adelaide Hospital Clinical Project Grant	$25,000

Medical students

Alyssa Fitzpatrick (co-supervisor), Summer Scholarship (2010), MBBS Year 4&5 Research component (2010-11), University of Adelaide

Undergraduate student co-supervision of laboratory-based research projects

Sean Burton (2007) Physiology III, Bachelor of Science, University of Adelaide

MJ Vink, BJ Rositano, EF Jackson (2011) Structural Cell Biol III, Bachelor of Science, University of Adelaide

Shinjie Wong (2013) Summer Scholarship, University of Adelaide

Roseanna Hunter (2014) Summer Scholarship, Freemasons Foundation Centre for Men’s Health, University of Adelaide

K Bremert, C Webber, L Day (2015) Investigative Cell Biol II, Bachelor of Science, University of Adelaide

Kayla Bremert (2016) Summer Scholarship, University of Adelaide

Joshua Hodgson (2019) Summer Scholarship, University of Adelaide

Teaching & assessment

Practical supervisor/tutor/assessor (2004) University of Adelaide, Bachelor of Science, Biology I

Practical supervisor/tutor/assessor (2005) University of Adelaide, Bachelor of Science, Physiology III

Examiner Honours students (2007-10) University of Adelaide, Department of Obstetrics and Gynaecology

Poster award judge (2009-11) The Australian Society for Medical Research, South Australian Meeting

Examiner Honours students (2020-2021) University of Adelaide, BHMSc

Guest lecturer (2016-current) University of Adelaide, School of Medicine, Integrative Cell Biology III

Current Higher Degree by Research Supervision (University of Adelaide)

Date	Role	Research Topic	Program	Degree Type	Student Load	Student Name
2021	Principal Supervisor	Overcoming resistance to cyclin-dependent kinase inhibition in prostate cancer	Doctor of Philosophy	Doctorate	Full Time	Mr Joshua Thomas Hodgson

Past Higher Degree by Research Supervision (University of Adelaide)

Date	Role	Research Topic	Program	Degree Type	Student Load	Student Name
2020 - 2024	Principal Supervisor	Investigating How Fatty Acid Elongation Promotes Prostate Carcinogenesis	Doctor of Philosophy	Doctorate	Full Time	Miss Deanna Catherine Miller
2018 - 2024	Co-Supervisor	Novel co-targets to improve androgen receptor inhibition in prostate cancer	Doctor of Philosophy under a Jointly-awarded Degree Agreement with	Doctorate	Full Time	Miss Josephine Ataa Hinneh
2013 - 2016	Co-Supervisor	Elucidating the Molecular Action of Synthetic Heat Shock Protein 90 Inhibitors in Prostate Cancer	Doctor of Philosophy	Doctorate	Full Time	Miss Heather Krista Armstrong

Committee Memberships

Date	Role	Committee	Institution	Country
2023 - ongoing	Member	Cancer Council Postdoctoral Research Fellowship Grant Assessment Committee	Cancer Council Victoria	Australia
2016 - ongoing	Member	School of Medicine Early/Mid-Career Research Committee	University of Adelaide	Australia
2015 - ongoing	Member	Faculty of Health Sciences Low Risk Human Research Ethics Committee	University of Adelaide	Australia

Position: Research Fellow
Phone: 81284361
Email: margaret.centenera@adelaide.edu.au
Campus: North Terrace
Building: SAHMRI - Prostate Cancer Research Group, floor 5
Org Unit: South Australian Immunogenomics Cancer Institute